GlassScriptPhysician profile
Calvin L Dixon
NPI 1568428183
$3,757.48
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,757.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,940.81 | 2019 | |
| Mylan Specialty L.P. | $215.82 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.49 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $138.25 | 2019 | |
| Sunovion Pharmaceuticals INC. | $134.44 | 2019 | |
| Glaxosmithkline, LLC. | $35.37 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $33.76 | 2019 | |
| Mallinckrodt Enterprises LLC | $32.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.79 | 2019 |
Research and ownership
$21,782.51 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Calvin Dixon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.